JP2003528819A - オピオイドおよびそのアンタゴニストに関する新規方法および組成物 - Google Patents

オピオイドおよびそのアンタゴニストに関する新規方法および組成物

Info

Publication number
JP2003528819A
JP2003528819A JP2001539402A JP2001539402A JP2003528819A JP 2003528819 A JP2003528819 A JP 2003528819A JP 2001539402 A JP2001539402 A JP 2001539402A JP 2001539402 A JP2001539402 A JP 2001539402A JP 2003528819 A JP2003528819 A JP 2003528819A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
substituted alkyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001539402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528819A5 (enExample
Inventor
ファーラー，ジョン・ジェイ
Original Assignee
アドラー コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドラー コーポレーション filed Critical アドラー コーポレーション
Publication of JP2003528819A publication Critical patent/JP2003528819A/ja
Publication of JP2003528819A5 publication Critical patent/JP2003528819A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001539402A 1999-11-29 2000-11-29 オピオイドおよびそのアンタゴニストに関する新規方法および組成物 Pending JP2003528819A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45080699A 1999-11-29 1999-11-29
US09/450,806 1999-11-29
PCT/US2000/042315 WO2001037785A2 (en) 1999-11-29 2000-11-29 Novel methods and compositions involving opioids and antagonists thereof

Publications (2)

Publication Number Publication Date
JP2003528819A true JP2003528819A (ja) 2003-09-30
JP2003528819A5 JP2003528819A5 (enExample) 2008-01-24

Family

ID=23789563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001539402A Pending JP2003528819A (ja) 1999-11-29 2000-11-29 オピオイドおよびそのアンタゴニストに関する新規方法および組成物

Country Status (13)

Country Link
EP (1) EP1244447B1 (enExample)
JP (1) JP2003528819A (enExample)
AU (1) AU784541B2 (enExample)
CA (1) CA2392362A1 (enExample)
CY (1) CY1106359T1 (enExample)
DE (1) DE60032940T2 (enExample)
DK (1) DK1244447T3 (enExample)
ES (1) ES2278647T3 (enExample)
IL (2) IL149600A0 (enExample)
MX (1) MXPA02005335A (enExample)
NZ (1) NZ518562A (enExample)
PT (1) PT1244447E (enExample)
WO (1) WO2001037785A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064780A1 (ja) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. 便秘治療剤
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
JP2006527775A (ja) * 2003-06-16 2006-12-07 アドラー コーポレーション 置換されたピペリジン化合物とその使用方法
JP2008501713A (ja) * 2004-06-04 2008-01-24 アドラー コーポレーション オピオイドアンタゴニストを含有する組成物
JP2010535814A (ja) * 2007-08-09 2010-11-25 レンセラール ポリテクニック インスティチュート 第四級オピオイドカルボキサミド
JP2010540648A (ja) * 2007-10-01 2010-12-24 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
JP2011505348A (ja) * 2007-11-30 2011-02-24 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン化合物
WO2020213911A1 (ko) * 2019-04-19 2020-10-22 연성정밀화학(주) 날데메딘의 제조방법

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP1404323B1 (en) * 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
PT2425824T (pt) 2002-04-05 2017-08-23 Mundipharma Farmacêutica Lda Preparação farmacêutica contendo oxicodona e naloxona
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CA2600350C (en) 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
EP1762569A1 (en) * 2005-09-12 2007-03-14 Alcasynn Pharmaceuticals Gmbh Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics
WO2007121916A2 (en) 2006-04-21 2007-11-01 Dsm Ip Assets B.V. Use of opioid receptor antagonists
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ME03298B (me) 2009-03-10 2019-07-20 Euro Celtique Sa Farmaceutske kombinacije sa trenutnim oslobađanjem које obuhvataju oksikodon i nalokson
SI2506712T1 (sl) 2009-12-04 2019-06-28 Alkermes Pharma Ireland Limited, Derivati morfinana za zdravljenje prevelikega odmerka mamil
WO2011119605A2 (en) 2010-03-22 2011-09-29 Rensselaer Polytechnic Institute Carboxamide biosiosteres of opiates
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
PT2725908T (pt) 2011-06-29 2017-08-31 Alkermes Inc Compostos opioides de ação periférica
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
WO2014172482A1 (en) * 2013-04-17 2014-10-23 Robert Alfred Volkmann Compounds for treatment of pain
US10072018B2 (en) 2013-04-17 2018-09-11 Biopharma Works Compounds for treatment of pain
CN105517551A (zh) 2013-07-23 2016-04-20 欧洲凯尔特公司 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4582835A (en) * 1983-12-06 1986-04-15 Reckitt & Colman Products Limited Analgesic compositions
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
EP0287339A2 (en) * 1987-04-16 1988-10-19 Eli Lilly And Company Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4582835A (en) * 1983-12-06 1986-04-15 Reckitt & Colman Products Limited Analgesic compositions
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
EP0287339A2 (en) * 1987-04-16 1988-10-19 Eli Lilly And Company Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527775A (ja) * 2003-06-16 2006-12-07 アドラー コーポレーション 置換されたピペリジン化合物とその使用方法
JP4889487B2 (ja) * 2003-06-16 2012-03-07 アドラー コーポレーション 置換されたピペリジン化合物とその使用方法
JP2008501713A (ja) * 2004-06-04 2008-01-24 アドラー コーポレーション オピオイドアンタゴニストを含有する組成物
WO2006064780A1 (ja) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. 便秘治療剤
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
WO2006126637A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
AU2006250390B2 (en) * 2005-05-25 2010-07-08 Shionogi And Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
USRE46375E1 (en) 2005-05-25 2017-04-25 Shionogi & Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
USRE46365E1 (en) 2005-05-25 2017-04-11 Shionogi & Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US8084460B2 (en) 2005-05-25 2011-12-27 Shionogi & Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US8536192B2 (en) 2005-05-25 2013-09-17 Shionogi & Co. Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
JP2010535814A (ja) * 2007-08-09 2010-11-25 レンセラール ポリテクニック インスティチュート 第四級オピオイドカルボキサミド
JP2015028074A (ja) * 2007-10-01 2015-02-12 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
JP2010540648A (ja) * 2007-10-01 2010-12-24 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
JP2011505348A (ja) * 2007-11-30 2011-02-24 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン化合物
WO2020213911A1 (ko) * 2019-04-19 2020-10-22 연성정밀화학(주) 날데메딘의 제조방법
US12325712B2 (en) 2019-04-19 2025-06-10 Yonsung Fine Chemical Co., Ltd. Method for preparing naldemedine

Also Published As

Publication number Publication date
AU784541B2 (en) 2006-04-27
DK1244447T3 (da) 2007-04-23
WO2001037785A9 (en) 2002-08-29
AU3970601A (en) 2001-06-04
EP1244447B1 (en) 2007-01-10
IL149600A (en) 2010-06-16
DE60032940T2 (de) 2007-11-08
IL149600A0 (en) 2002-11-10
CA2392362A1 (en) 2001-05-31
EP1244447A2 (en) 2002-10-02
WO2001037785A2 (en) 2001-05-31
ES2278647T3 (es) 2007-08-16
EP1244447A4 (en) 2003-06-04
CY1106359T1 (el) 2011-10-12
PT1244447E (pt) 2007-02-28
NZ518562A (en) 2005-04-29
DE60032940D1 (de) 2007-02-22
MXPA02005335A (es) 2003-01-28
WO2001037785A3 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
JP2003528819A (ja) オピオイドおよびそのアンタゴニストに関する新規方法および組成物
US6451806B2 (en) Methods and compositions involving opioids and antagonists thereof
JP5460771B2 (ja) イレウスの治療及び予防のための新規な方法
US6469030B2 (en) Methods for the treatment and prevention of ileus
US20150126554A1 (en) Methods of preventing and treating gastrointestinal dysfunction
JP2008501713A (ja) オピオイドアンタゴニストを含有する組成物
WO2001041705A2 (en) Novel methods for the treatment and prevention of dizziness and pruritus
EP0938898A2 (en) Treatment of pruritus
US20060052409A1 (en) Therapeutic or preventive agent for nausea/vomiting
US20070092576A1 (en) Compositions containing opioid antagonists
US7501433B2 (en) Opioid and opioid-like compounds and uses thereof
WO2022119862A1 (en) Treatment of pain and neurological conditions
US20060211733A1 (en) Methods of preventing and treating opioid bowel dysfunction
JPWO1997006139A1 (ja) 麻薬性鎮痛剤の依存・耐性形成抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110506

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110525

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120402